Novartis AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2003-03-31
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Novartis
- Registration Number
- NCT00057265
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
- Conditions
- Colorectal NeoplasmsColonic NeoplasmsRectal Neoplasms
- Interventions
- First Posted Date
- 2003-03-14
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1168
- Registration Number
- NCT00056459
- Locations
- ๐บ๐ธ
Center for Oncology Research & Treatment, PA, Dallas, Texas, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Care Center, Los Angeles, California, United States
๐บ๐ธPeachtree Hematology and Oncology, Atlanta, Georgia, United States
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
- Conditions
- Breast CancerMultiple MyelomaProstate Cancer
- First Posted Date
- 2002-01-10
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 500
- Registration Number
- NCT00029224
- Locations
- ๐บ๐ธ
Osceola Cancer Center, Kissimmee, Florida, United States
๐บ๐ธStockton Hematology Oncology Medical Group, Stockton, California, United States
๐บ๐ธHematology-Oncology Associates PC, Albuquerque, New Mexico, United States
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00002394
- Locations
- ๐บ๐ธ
Univ of Texas Med Branch, Galveston, Texas, United States
๐บ๐ธHampton Roads Med Specialists, Hampton, Virginia, United States
๐บ๐ธTherafirst Med Ctr, Fort Lauderdale, Florida, United States
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
- Conditions
- Alzheimer DiseaseCognition Disorders
- First Posted Date
- 1999-11-01
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Registration Number
- NCT00000174
- Locations
- ๐บ๐ธ
St. Louis University, St. Louis, Missouri, United States
๐บ๐ธClinical Studies, Ltd., Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธSt. Paul Medical Center, Dallas, Texas, United States